Evaluation of an intensive insulin transition protocol in the intensive care unit setting: a before and after study
Main Article Content
Keywords
Abstract
The benefits of controlling blood glucose levels in intensive care units (ICUs) are well documented.
Objective: This study determined the effectiveness and safety of a standardized transition order set for converting a continuous insulin infusion to a subcutaneous insulin regimen in non-cardiovascular surgery ICUs patient population.
Methods: A retrospective study was conducted. Patients presenting with diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome were excluded. One hundred patients were included prior to and 100 patients were included after initiating the transition order set. Blood glucose control was reviewed for up to 72 hours following the transition.
Results: A total of 115 patients were included in data analysis: 85 prior to and 30 after transition protocol. All patients transitioned using the protocol were transitioned to basal insulin, compared to only 40% of the prior to protocol group. Patients transitioned correctly per the transition order set, “per protocol,” had 54% of blood sugars within the desired range, no increase in hypoglycemic events, and on average 5.56 hyperglycemic events (blood glucose >180 mg/dL) per person during the 72 hours compared to 6.68 and 9.00 for the prior to protocol group and the “off protocol” group (transitioned different than the protocol recommended), respectively (p= 0.05). There were significant differences in blood sugar control at 48 and 72 hours between the “per protocol” and “off protocol” groups (p= 0.01) and a 40% reduction in sliding scale or correctional insulin coverage.
Conclusion: The addition of basal insulin to transition regimens resulted in fewer hyperglycemic events with no increase in hypoglycemic events. Patients transitioned “per protocol” had better glucose control demonstrated by: less hyperglycemic events, lower mean blood glucose levels at 48 and 72 hours, and lower need for correctional insulin. These findings showed benefits of glycemic control in the ICU by following a standardized transition protocol.
Keywords: Insulin. Blood Glucose. Intensive Care Units. Postoperative Care. United States.
References
2. van den Berghe G. How does blood glucose control with insulin save lives in the intensive care. J Clin Invest. 2004;114(9):1187-1195.
3. van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, van Wijngaerden E, Bobbaers H, Bouillon R. Intensive Insulin Therapy in the Medical ICU. N Engl J Med. 2006;354(5):449-461.
4. McCowen KC, Malhotra A, Bistrian BR. Stress-Induced Hyperglycemia. Crit Care Clin. 2001;17(1):107-124.
5. Pittas AG, Siegel, Lau J. Insulin Therapy for Critically Ill Hospitalized Patients. Arch Intern Med. 2004;164(18):2005-2011.
6. DeSantis AJ, Schmeltz LR, Schmidt K, O'Shea-Mahler E, Rhee C, Wells A, Brandt S, Peterson S, Molitch ME. Inpatient Management of Hyperglycemia: The Northwestern Experience. Endocr Pract. 2006;12(5):491-505.
7. Shogbon AO, Levy S. Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. Am J Health Syst Pharm. 2010;67(10):798-805.
8. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus Conventional Glucose Control in Critically Ill Patients. N Engl J Med. 2009;360(13):1283-1297.
9. Furnary AP, Braithwaite SS. Effects of Outcome on In-Hospital Transition from Intravenous Insulin Infusion to Subcutaneous Therapy. Am J Cardiol. 2006;98(4):557-564.
10. Weant KA, Ladha A. Conversion from Continuous Insulin Infusions to Subcutaneous Insulin in Critically Ill Patients. Ann Pharmacother. 2009;43(4):629-634.
11. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA. Influence of Individual Characteristics on Outcome of Glycemic Control in Intensive Care Unit Patients With or Without Diabetes Mellitus. Mayo Clin Proc. 2005;80(12):1558-1567.
12. Schmeltz LR, DeSantis AJ, Schmidt K, O'Shea-Mahler E, Rhee C, Brandt S, Peterson S, Molitch ME. Conversion of Intravenous Insulin Infusions to Subcutaneously Administered Insulin Glargine in Patients with Hyperglycemia. Endocr Pract. 2006;12(6):641-650.
13. Olansky L, Sharon S, Lover C, Yared JP, Hoogwerf B. Cleveland Clinic Cardiovascular Intensive Care Unit Insulin Conversion Protocol. J Diabetes Sci Technol. 2009;3(3):478-486.
14. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologist and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15(4):353-369.
15. Kavanagh BP, McCowen KC. Glycemic Control in the ICU. N Engl J Med. 2010;363(26):2540-2546.
16. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control: a call to action. Diabetes Care. 2006;29(8):1955-1962.
17. Edelman S, Dailey G, Flood T, Kuritizky L, Renda S. A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care. 2007;1:9.
18. Davidson PC, Steed RD, Bode BW. Glucommander: A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation. Diabetes Care. 2005;28(10):2418-2423.
19. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.
20. Schmeltz LR, DeSantis AJ, Schmidt K, O'Shea-Mahler E, Rhee C, Brandt S, Peterson S, Molitch ME. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract. 2006;12(6):641-650.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.